Recent advances in the diagnosis and therapy of peanut allergy

Expert Review of Clinical Immunology

Volumn 9, Issue 6, 2013, Pages 551-560

  Sheikh, Saira Z ^a   Burks, A Wesley ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

allergen nonspecific; allergen specific; allergy; component resolved; diagnosis; diagnostics; IgE mediated; immunotherapy; peanut; treatment

Indexed keywords

ALLERGEN; EPITOPE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; TALIZUMAB;

CLINICAL TRIAL; DESENSITIZATION; FOOD ALLERGY; FOOD INTAKE; HERBAL MEDICINE; HUMAN; IMMUNOTHERAPY; MOLECULAR DIAGNOSTICS; NONHUMAN; PEANUT ALLERGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PROTEIN INTAKE; PROTEIN MICROARRAY; REVIEW;

CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN E; PEANUT HYPERSENSITIVITY; SKIN TESTS;

EID: 84878709442     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.33     Document Type: Review

References (95)

1. Sicherer SH, Muñoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: a 5-year follow-up study. J. Allergy Clin. Immunol. 112(6), 1203-1207 (2003).
2. Grundy J, Matthews S, Bateman B, Dean T, Arshad SH. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J. Allergy Clin. Immunol. 110(5), 784-789 (2002).
3. Kagan RS, Joseph L, Dufresne C, et al. Prevalence of peanut allergy in primaryschool children in Montreal, Canada. J. Allergy Clin. Immunol. 112(6), 1223-1228 (2003).
4. Neuman-Sunshine DL, Eckman JA, Keet CA, et al. The natural history of persistent peanut allergy. Ann. Allergy Asthma Immunol. 108(5), 326.e3-331.e3 (2012).
5. Sicherer SH, Sampson HA. Food allergy. J. Allergy Clin. Immunol. 125(2 Suppl. 2), S116-S125 (2010).
6. Hourihane JO, Aiken R, Briggs R, et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J. Allergy Clin. Immunol. 119(5), 1197-1202 (2007).
7. Mullins RJ, Dear KB, Tang ML. Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. J. Allergy Clin. Immunol. 123(3), 689-693 (2009).
8. Venter C, Hasan Arshad S, Grundy J, et al. Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy 65(1), 103-108 (2010).
9. Ben-Shoshan M, Kagan RS, Alizadehfar R, et al. Is the prevalence of peanut allergy increasing? A 5-year follow-up study in children in Montreal. J. Allergy Clin. Immunol. 123(4), 783-788 (2009).
10. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J. Allergy Clin. Immunol. 125(6), 1322-1326 (2010).
11. Sicherer SH. Epidemiology of food allergy. J. Allergy Clin. Immunol. 127(3), 594-602 (2011).
12. Osborne NJ, Koplin JJ, Martin PE, et al.; HealthNuts Investigators. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J. Allergy Clin. Immunol. 127(3), 668.e1-676.e1 (2011).
13. Hourihane JO, Roberts SA, Warner JO. Resolution of peanut allergy: case-control study. BMJ 316(7140), 1271-1275 (1998).
14. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. J. Allergy Clin. Immunol. 107(2), 367-374 (2001).
15. Clark AT, Ewan PW. Good prognosis, clinical features, and circumstances of peanut and tree nut reactions in children treated by a specialist allergy center. J. Allergy Clin. Immunol. 122(2), 286-289 (2008).
16. Yu JW, Kagan R, Verreault N, et al. Accidental ingestions in children with peanut allergy. J. Allergy Clin. Immunol. 118(2), 466-472 (2006).
17. Ewan PW, Clark AT. Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice. Clin. Exp. Allergy 35(6), 751-756 (2005).
18. Fleischer DM, Perry TT, Atkins D, et al. Allergic reactions to foods in preschoolaged children in a prospective observational food allergy study. Pediatrics 130(1), e25-e32 (2012).
19. Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J. Allergy Clin. Immunol. 119(4), 1016-1018 (2007).
20. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J. Allergy Clin. Immunol. 107(1), 191-193 (2001).
21. Boyce JA, Assa'ad A, Burks AW, et al.; NIAID-Sponsored Expert Panel. Guidelines for the Diagnosis and Management of Food Allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. J. Allergy Clin. Immunol. 126(6), 1105-1118 (2010).
22. Kattan JD, Wang J. Allergen component testing for food allergy: ready for prime time? Curr. Allergy Asthma Rep. 13(1), 58-63 (2013).
23. Fox AT, Sasieni P, du Toit G, Syed H, Lack G. Household peanut consumption as a risk factor for the development of peanut allergy. J. Allergy Clin. Immunol. 123(2), 417-423 (2009).
24. Sicherer SH, Burks AW, Sampson HA. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics 102(1), e6 (1998).
25. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst. Rev. 9, CD000133 (2012).
26. Maslova E, Granström C, Hansen S, et al. Peanut and tree nut consumption during pregnancy and allergic disease in children -should mothers decrease their intake? Longitudinal evidence from the Danish National Birth Cohort. J. Allergy Clin. Immunol. 130(3), 724-732 (2012).
27. Miller DS, Brown MP, Howley PM, Hayball JD. Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy. Expert Rev. Vaccines 11(12), 1471-1481 (2012).
28. Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J. Allergy Clin. Immunol. 127(3), 661-667 (2011).
29. Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J. Allergy Clin. Immunol. 107(5), 891-896 (2001).
30. Burks AW. Peanut allergy. Lancet 371(9623), 1538-1546 (2008).
31. Koppelman SJ, Wensing M, Ertmann M, Knulst AC, Knol EF. Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil-histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. Clin. Exp. Allergy 34(4), 583-590 (2004).
32. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. J. Allergy Clin. Immunol. 127(3), 684-685 (2011).
33. Dang TD, Tang M, Choo S, et al.; HealthNuts study. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J. Allergy Clin. Immunol. 129(4), 1056-1063 (2012).
34. Osborne NJ, Koplin JJ, Martin PE, et al.; HealthNuts Study Investigators. The HealthNuts population-based study of paediatric food allergy: validity, safety and acceptability. Clin. Exp. Allergy 40(10), 1516-1522 (2010).
35. Vereda A, van Hage M, Ahlstedt S, et al. Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions. J. Allergy Clin. Immunol. 127(3), 603-607 (2011).
36. Pedrosa M, Boyano-Martínez T, García-Ara MC, Caballero T, Quirce S. Peanut seed storage proteins are responsible for clinical reactivity in Spanish peanutallergic children. Pediatr. Allergy Immunol. 23(7), 654-659 (2012).
37. Chiang WC, Pons L, Kidon MI, Liew WK, Goh A, Wesley Burks A. Serological and clinical characteristics of children with peanut sensitization in an Asian community. Pediatr. Allergy Immunol. 21(2 Pt 2), e429-e438 (2010).
38. Lin YT, Wu CT, Cheng JH, Huang JL, Yeh KW. Patterns of sensitization to peanut allergen components in Taiwanese Preschool children. J. Microbiol. Immunol. Infect. 45(2), 90-95 (2012).
39. Sicherer S. Advances in diagnosing peanut allergy. J. Allergy Clin. Immunol.: In Practice 1(1), 1-13 (2013).
40. Movérare R, Ahlstedt S, Bengtsson U, et al. Evaluation of IgE antibodies to recombinant peanut allergens in patients with reported reactions to peanut. Int. Arch. Allergy Immunol. 156(3), 282-290 (2011).
41. Asarnoj A, Nilsson C, Lidholm J, et al. Peanut component Ara h 8 sensitization and tolerance to peanut. J. Allergy Clin. Immunol. 130(2), 468-472 (2012).
42. Peeters KA, Koppelman SJ, van Hoffen E, et al. Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? Clin. Exp. Allergy 37(1), 108-115 (2007).
43. Palmer GW, Dibbern DA Jr, Burks AW, et al. Comparative potency of Ara h 1 and Ara h 2 in immunochemical and functional assays of allergenicity. Clin. Immunol. 115(3), 302-312 (2005).
44. Astier C, Morisset M, Roitel O, et al. Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J. Allergy Clin. Immunol. 118(1), 250-256 (2006).
45. Caubet JC, Sampson HA. Beyond skin testing: state of the art and new horizons in food allergy diagnostic testing. Immunol. Allergy Clin. North Am. 32(1), 97-109 (2012).
46. Hamilton RG, Saito H. IgE antibody concentration, specific activity, clonality, and affinity measures from future diagnostic confirmatory tests. J. Allergy Clin. Immunol. 122(2), 305-306 (2008).
47. Renault NK, Gaddipati SR, Wulfert F, et al. Multiple protein extract microarray for profiling human food-specific immunoglobulins A, M, G and E. J. Immunol. Methods 364(1-2), 21-32 (2011).
48. Sampson HA. Improving in vitro tests for the diagnosis of food hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 2(3), 257-261 (2002).
49. Shreffler WG, Beyer K, Chu TH, Burks AW, Sampson HA. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J. Allergy Clin. Immunol. 113(4), 776-782 (2004).
50. Flinterman AE, Knol EF, Lencer DA, et al. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J. Allergy Clin. Immunol. 121(3), 737.e10-743.e10 (2008).
51. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the diagnosis of allergy: technical issues and critical factors. Allergy 64(9), 1319-1326 (2009).
52. Flinterman AE, Pasmans SG, den Hartog Jager CF, et al. T-cell responses to major peanut allergens in children with and without peanut allergy. Clin. Exp. Allergy 40(4), 590-597 (2010).
53. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J. Allergy Clin. Immunol. 90(2), 256-262 (1992).
54. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J. Allergy Clin. Immunol. 99(6 Pt 1), 744-751 (1997).
55. Stahl MC, Rans TS. Potential therapies for peanut allergy. Ann. Allergy Asthma Immunol. 106(3), 179-187; quiz 188 (2011).
56. Patriarca G, Nucera E, Roncallo C, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment. Pharmacol. Ther. 17(3), 459-465 (2003).
57. Buchanan AD, Green TD, Jones SM, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol. 119(1), 199-205 (2007).
58. Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J. Allergy Clin. Immunol. 122(6), 1154-1160 (2008).
59. Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. J. Allergy Clin. Immunol. 127(3), 558-573; quiz 574 (2011).
60. Kulis M, Vickery BP, Burks AW. Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response. Immunol. Res. 49(1-3), 216-226 (2011).
61. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 62(11), 1261-1269 (2007).
62. Rolinck-Werninghaus C, Staden U, Mehl A, Hamelmann E, Beyer K, Niggemann B. Specific oral tolerance induction with food in children: transient or persistent effect on food allergy? Allergy 60(10), 1320-1322 (2005).
63. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J. Allergy Clin. Immunol. 124(2), 292-300.e97 (2009).
64. Hofmann AM, Scurlock AM, Jones SM, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J. Allergy Clin. Immunol. 124(2), 286.e1-291.e1 (2009).
65. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW. Successful oral tolerance induction in severe peanut allergy. Allergy 64(8), 1218-1220 (2009).
66. Blumchen K, Ulbricht H, Staden U, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J. Allergy Clin. Immunol. 126(1), 83.e1-91.e1 (2010).
67. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin. Exp. Allergy 41(9), 1273-1281 (2011).
68. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol. 127(3), 654-660 (2011).
69. Sánchez-García S, Rodríguez Del Río P, Escudero C, Martínez-Gómez MJ, Ibáñez MD. Possible eosinophilic esophagitis induced by milk oral immunotherapy. J. Allergy Clin. Immunol. 129(4), 1155-1157 (2012).
70. Varshney P, Steele PH, Vickery BP, et al. Adverse reactions during peanut oral immunotherapy home dosing. J. Allergy Clin. Immunol. 124(6), 1351-1352 (2009).
71. Kim EH, Burks W. Managing food allergy in childhood. Curr. Opin. Pediatr. 24(5), 615-620 (2012).
72. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(Suppl. 91), 1-59 (2009).
73. Passalacqua G, Lombardi C, Troise C, Canonica GW. Sublingual immunotherapy: certainties, unmet needs and future directions. Eur. Ann. Allergy Clin. Immunol. 41(6), 163-170 (2009).
74. Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J. Allergy Clin. Immunol. 127(3), 640.e1-646.e1 (2011).
75. Kulis M, Saba K, Kim EH, et al. Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J. Allergy Clin. Immunol. 129(4), 1159-1162 (2012).
76. Fleischer DM, Burks AW, Vickery BP, et al.; Consortium of Food Allergy Research (CoFAR). Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J. Allergy Clin. Immunol. 131(1), 119.e1-127.e1 (2013).
77. Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H, Benhamou PH. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J. Allergy Clin. Immunol. 125(5), 1165-1167 (2010).
78. Mondoulet L, Dioszeghy V, Vanoirbeek JA, Nemery B, Dupont C, Benhamou PH. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int. Arch. Allergy Immunol. 154(4), 299-309 (2011).
79. Scurlock AM, Burks AW. Peanut allergenicity. Ann. Allergy Asthma Immunol. 93(5 Suppl. 3), S12-S18 (2004).
80. Li XM, Srivastava K, Huleatt JW, Bottomly K, Burks AW, Sampson HA. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J. Immunol. 170(6), 3289-3295 (2003).
81. Li XM, Srivastava K, Grishin A, et al. Persistent protective effect of heat-killed Escherichia coli producing 'engineered', recombinant peanut proteins in a murine model of peanut allergy. J. Allergy Clin. Immunol. 112(1), 159-167 (2003).
82. Leung DY, Sampson HA, Yunginger JW, et al.; Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 348(11), 986-993 (2003).
83. Sampson HA, Leung DY, Burks AW, et al. A Phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J. Allergy Clin. Immunol. 127(5), 1309.e1-1310.e1 (2011).
84. Li XM, Brown L. Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J. Allergy Clin. Immunol. 123(2), 297-306; quiz 307 (2009).
85. Li XM, Zhang TF, Huang CK, et al. Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J. Allergy Clin. Immunol. 108(4), 639-646 (2001).
86. Srivastava KD, Kattan JD, Zou ZM, et al. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J. Allergy Clin. Immunol. 115(1), 171-178 (2005).
87. Wang J, Patil SP, Yang N, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, Phase 1 study. Ann. Allergy Asthma Immunol. 105(1), 75-84 (2010).
88. Patil SP, Wang J, Song Y, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended Phase I study. J. Allergy Clin. Immunol. 128(6), 1259.e2-1265.e2 (2011).
89. Srivastava K, Yang N, Chen Y, et al. Efficacy, safety and immunological actions of butanol-extracted Food Allergy Herbal Formula-2 on peanut anaphylaxis. Clin. Exp. Allergy 41(4), 582-591 (2011).
90. Srivastava KD, Bardina L, Sampson HA, Li XM. Efficacy and immunological actions of FAHF-2 in a murine model of multiple food allergies. Ann. Allergy Asthma Immunol. 108(5), 351.e1-358.e1 (2012).
91. ClinicalTrials.gov. Epicutaneous immunotherapy in peanut allergy in children (ARACHILD). www.clinicaltrials.gov/ct2/show/NCT01197053
92. ClinicalTrials.gov. Safety of epicutaneous immunotherapy for the treatment of peanut allergy. www.clinicaltrials.gov/ct2/show/NCT01170286
93. ClinicalTrials.gov. Peanut allergy vaccine study in healthy and peanut-allergic adults. www.clinicaltrials.gov/ct2/show/NCT00850668
94. ClinicalTrials.gov. Peanut oral immunotherapy and anti-immunoglobulin E (IgE) for peanut allergy. www.clinicaltrials.gov/ct2/show/NCT00932282
95. ClinicalTrials.gov. Therapeutic effect of Chinese herbal medicine on food allergy (FAHF-2). www.clinicaltrials.gov/ct2/show/NCT00602160